## EXPD: Expeditors International of Was - XLI: Industrials

### Executive Summary

No thesis match: MRS_10 2.5% below STRENGTH zone (3.0-6.0%); PEG 5.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($143.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Thrivent Financial for Lutherans Sells 72,654 Shares of Expeditors International of Washington, Inc. $EXPD**
- Source: MarketBeat | 20251215T120822 | Somewhat-Bearish | Relevance: 100%
- Thrivent Financial for Lutherans has reduced its stake in Expeditors International of Washington, Inc. (NASDAQ:EXPD) by 10.2%, selling 72,654 shares, though it still owns 637,173 shares valued at approximately $72.8 million. The company recently declared a $0.77 dividend, payable on December 15th, with an unusually high reported dividend yield of 105.0%. Despite institutional investors owning 94.02% of the company, insiders have been selling shares, and analysts currently have a "Reduce" rating with an average price target of $128.20.

**2. Stifel Maintains Expeditors International of Washington (EXPD) Hold Recommendation**
- Source: Nasdaq | 20251217T070747 | Somewhat-Bearish | Relevance: 100%
- Stifel has maintained its Hold recommendation for Expeditors International of Washington (EXPD). The average one-year price target suggests a 12.75% downside from the latest closing price. Financial institutions are showing an increased interest, with total shares owned by institutions rising by 2.41% in the last quarter.

**3. Expeditors International of Washington (NASDAQ:EXPD) Given New $136.00 Price Target at Stifel Nicolaus**
- Source: MarketBeat | 20251216T172824 | Somewhat-Bearish | Relevance: 100%
- Stifel Nicolaus has raised its price target for Expeditors International of Washington (NASDAQ:EXPD) to $136.00 from $130.00, while maintaining a "hold" rating, suggesting a potential downside from its previous close. Other analysts have also recently adjusted their price targets and ratings for EXPD, resulting in a consensus "Reduce" rating with an average target of $128.80. The article also notes recent insider selling despite significant institutional accumulation of the stock.

**4. Is C.H. Robinson Stock Outperforming the Dow?**
- Source: Barchart.com | 20251216T073037 | Somewhat-Bullish | Relevance: 74%
- C.H. Robinson Worldwide, Inc. (CHRW) stock has significantly outperformed the Dow Jones Industrial Average ($DOWI) over the past three months, 52 weeks, and year-to-date, signaling strong investor confidence despite revenue declines. The company reaffirmed its profitability narrative by raising its 2026 operating income target and trading above analyst price targets, with a "Moderate Buy" rating. This performance also outpaces its rival, Expeditors International of Washington, Inc. (EXPD).

**5. Is C.H. Robinson Stock Outperforming the Dow?**
- Source: Markets Financial Content | 20251216T070736 | Somewhat-Bullish | Relevance: 63%
- C.H. Robinson Worldwide, Inc. (CHRW) stock has significantly outperformed the Dow Jones Industrial Average, with gains of 18.3% in three months, 41.5% in 52 weeks, and 52.6% year-to-date. This strong performance is supported by robust Q3 2025 adjusted EPS growth and an increased 2026 operating income target. Wall Street analysts maintain a "Moderate Buy" rating for CHRW, indicating continued confidence in its trajectory.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Stifel | $136 | $130 | +5% |
| 2025-12-08 | Morgan Stanley | $95 | $90 | +6% |
| 2025-11-17 | UBS | $166 | $138 | +20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Stifel | main | Hold |
| 2025-12-08 | Morgan Stanley | main | Underweight |
| 2025-11-17 | UBS | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.93M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (-0.9%)
- Blackrock Inc.: 9.2% (-10.1%)
- State Street Corpora: 5.8% (+5.1%)
- First Eagle Investme: 4.7% (+0.0%)
- LOOMIS SAYLES & CO L: 4.3% (+1.6%)

### Key Risks

1. Valuation stretched: PEG 5.3x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 5.29 signals overvaluation risk, limited margin of safety. Forward P/E 25.1x stretched relative to 2% growth. Quality metrics strong (ROE 36%, ROA 14%). Analyst sentiment positive (3 raises, avg +10%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.3B |
| Beta | 1.14 |
| 52W Range | $100.47 - $155.04 |
| Short Interest | 4.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.29 |
| Forward P/E | 25.1 |
| Current P/E | 25.5 |
| YoY Growth | 1.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 stable at 2.5% (minimal 5-day change). Below STRENGTH zone by 0.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.0% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.60), momentum weakening. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.46% (CS: 49) | Neutral |
| RSI_14 | 62.8 | Neutral |
| MACD Histogram | -0.60 | Bearish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.113x | Above |
| vs SMA200 | 1.241x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $149.91
- **Stop Loss:** $143.39 (4.3% risk)
- **Target:** $156.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 165
- **Position Value:** $24,735.15
- **Portfolio %:** 24.74%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-24 (Est: $1.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.39 | $1.64 | +18.1% |
| 2025Q2 | $1.24 | $1.34 | +7.9% |
| 2025Q1 | $1.35 | $1.47 | +9.1% |
| 2024Q4 | $1.44 | $1.68 | +16.7% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*